ASH 2023 | Unmet needs in LR-MDS: RBC transfusion-dependence
Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, addresses the unmet need for red blood cell (RBC) transfusion-dependence in patients with lower-risk myelodysplastic syndromes (LR-MDS). She mentions luspatercept as a potentially superior frontline treatment to the traditionally used epoetin alfa (eprex), alleviating the need for RBC transfusion. As well as this, the MATTERHORN trial (NCT03263091) has found that roxadustat is effective at reducing RBC transfusion dependence in patients with a higher transfusion burden. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Honoraria; Taiho: Honoraria, Research Funding; BMS: Honoraria, Research Funding.
